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a  b  s  t  r  a  c  t
Vaccines  are  among  the  most  cost-effective  interventions  against  infectious  diseases.  Many  candidate
vaccines  targeting  neglected  diseases  in  low- and  middle-income  countries  are  now  progressing  to  large-
scale  clinical  testing.  However,  controversy  surrounds  the  appropriate  design  of  vaccine  trials  and,  in
particular,  the  use  of unvaccinated  controls  (with  or  without  placebo)  when  an  efﬁcacious  vaccine  already
exists. This  paper  speciﬁes  four situations  in  which  placebo  use may  be acceptable,  provided  that  the  study
question  cannot  be answered  in  an active-controlled  trial  design;  the risks  of  delaying  or  foregoing  anrial design
thics
lacebo controls
isk
nternational research
efﬁcacious  vaccine  are  mitigated;  the  risks  of using  a  placebo  control  are justiﬁed  by  the  social  and  public
health  value  of the research;  and  the  research  is  responsive  to local  health  needs.  The four  situations
are:  (1)  developing  a locally  affordable  vaccine,  (2)  evaluating  the  local  safety  and  efﬁcacy  of  an  existing
vaccine,  (3) testing  a new  vaccine  when  an  existing  vaccine  is considered  inappropriate  for  local  use  (e.g.
based  on epidemiologic  or demographic  factors),  and  (4)  determining  the local  burden  of disease.
ublis© 2014  The  Authors.  P∗ Corresponding author. Tel.: +44 207 848 7113; fax: +44 207 848 7020.
E-mail address: annette.rid@kcl.ac.uk (A. Rid).
ttp://dx.doi.org/10.1016/j.vaccine.2014.04.022
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/3.0/).
1. BackgroundInfectious diseases continue to pose a tremendous burden of dis-
ease worldwide, especially in low- and middle-income countries
(LMICs) [1]. Vaccines exist for many common infectious diseases,
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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nd they are among the most cost-effective means of reducing this
urden. However, for many debilitating and life-threatening infec-
ious diseases in LMICs, vaccines either do not exist, or they are
nsufﬁciently efﬁcacious1 or unavailable to most of the population
ue to high cost.
Many vaccines targeting diseases prevalent in LMICs are cur-
ently under development. As investigators and sponsors plan
arge-scale clinical trials to test the safety and efﬁcacy of these new
accines, important ethical issues can arise in trial design, particu-
arly around the use of a placebo control arm when an efﬁcacious
accine already exists.
Randomised, placebo-controlled trials are widely considered
he gold standard for evaluating the safety and efﬁcacy of a new vac-
ine. In these trials, participants are randomized to receive either
he vaccine under investigation or a placebo (i.e. an inert substance,
uch as a saline injection). Randomisation and the use of placebo
nterventions are designed to control for confounding effects, such
hat signiﬁcant differences in disease incidence or adverse effects
etween the vaccine and control groups can likely be attributed to
he vaccine. However, randomised, placebo-controlled trial designs
ften raise ethical concerns when participants in the control arm
re deprived of an existing vaccine. Furthermore, testing a new vac-
ine against placebo is scientiﬁcally and ethically fraught when the
ypothesis being tested is whether an experimental vaccine is more
fﬁcacious than one already in use in the same or in other settings.
Currently, there is insufﬁcient and inconsistent guidance on how
o evaluate the use of placebo controls in vaccine trials. Most ethi-
al guidelines for research do not address vaccine trials speciﬁcally;
nd, in those that do, the guidance regarding placebo use is limited
2,3]. Moreover, general ethical guidelines for research – authored
y both national and international bodies – offer conﬂicting guid-
nce on the use of placebo controls [4–11]. Some guidelines call for
xclusion of placebo use altogether when there is a proven or estab-
ished effective intervention against the condition under study [10].
thers allow placebo use, provided the risks of withholding or
elaying the existing intervention are either negligible or there are
ompelling methodological reasons for including a placebo arm in
he trial [4,5,7–9].
Yet, the level of risk deemed acceptable when there are com-
elling reasons for placebo use varies greatly. Most guidelines
llow no more than minimal risks, excluding risks of serious or
rreversible harm [4,5,9] or allowing placebo use only in the case
f self-limiting disease [7]. In contrast, others set no explicit risk
imit in research that is relevant to the local population [8]. Some
ocuments openly acknowledge the “unresolved, or unresolvable,
onﬂict” around placebo use [5], a situation that has led inﬂuen-
ial regulators to disregard ethical guidance that they deem overly
estrictive [12].
The lack of consistent guidance on the use of placebo controls
aises signiﬁcant ethical concern. On the one hand, investigators
nd sponsors may  avoid conducting placebo-controlled trials when
n efﬁcacious vaccine exists, even if such trials are scientiﬁcally
ecessary and potentially justiﬁable. On the other hand, a lack of
lear guidance may  result in the conduct of placebo-controlled tri-
ls that are ultimately unethical.
. WHO  expert consultation
Against this backdrop, the WHO  Department of Ethics and Social
eterminants convened an expert consultation to provide recom-
endations on the use of placebo controls in vaccine trials in
ases where an efﬁcacious vaccine already exists. The focus was
1 We use the term “efﬁcacious” to indicate a vaccine that reduces the incidence
f  the target disease. This includes vaccines that may  have high or low efﬁcacy.2014) 4708–4712 4709
on large-scale clinical trials that test vaccines in Phases III and IV of
development (i.e. where preliminary testing of safety and immuno-
genicity, and sometimes efﬁcacy, has been completed in Phase I and
II trials). The panel, consisting of 20 experts from 11 countries, met
to discuss relevant issues and develop recommendations in con-
sultation with key stakeholders in international vaccine research
(Appendix). The present paper develops the discussion and con-
clusions from that meeting [13].
3. General ethical considerations
Given the high burden of infectious diseases, especially in LMICs,
there is an ethical imperative to develop and test new vaccines.
The recommendations from the panel therefore aim to facilitate
the conduct of vaccine research that is ethical, scientiﬁcally valid,
and designed to meet important public health needs.
While this paper focuses speciﬁcally on the use of placebo
controls, similar considerations apply to open designs in which a
placebo is not used, but an unvaccinated control group is included.
The following recommendations assume that other common
requirements for ethical research are respected [4,5]. In particu-
lar: Investigators and sponsors consult and collaborate with local
stakeholders in all phases of the research; research participants,
or their legal representatives, give voluntary and informed con-
sent to study participation; participants are free to withdraw from
research at any time, for any reason, without penalty; the research
addresses an important health problem and is responsive to local
health needs; the study design used minimizes risks and enhances
potential clinical beneﬁts for participants; the beneﬁts and burdens
of the research are justly distributed; and sponsors, in consultation
with national or local authorities, make provisions to ensure rea-
sonable post-trial access to interventions proven most efﬁcacious
to the population from which the research participants were drawn.
4. Ethical framework for placebo use in vaccine trials
To navigate the difﬁcult ethical terrain of using placebo con-
trols in vaccine trials, it is helpful to identify the conditions under
which placebo use is clearly acceptable and clearly unacceptable.
The following considerations assume that placebo interventions
(e.g. subcutaneous injections of saline solution) themselves pose
negligible risks.
Placebo use in vaccine trials is clearly acceptable when (a) no
efﬁcacious and safe vaccine exists and (b) the vaccine under consid-
eration is intended to beneﬁt the population in which the vaccine
is to be tested. In this situation, a placebo-controlled trial addresses
the locally relevant question regarding the extent to which the new
vaccine is better than nothing, and participants in the placebo arm
of the trial are not deprived of the clinical beneﬁts of an existing
efﬁcacious vaccine.
Placebo use in vaccine trials is clearly unacceptable when (a) a
highly efﬁcacious and safe vaccine exists and is currently accessi-
ble in the public health system of the country in which the trial is
planned and (b) the risks to participants of delaying or foregoing
the available vaccine cannot be adequately minimized or mitigated
(e.g. by providing counselling and education on behavioural dis-
ease prevention strategies, or ensuring adequate treatment for the
condition under study to prevent serious harm). In this situation, a
placebo-controlled trial would not address a question that is rele-
vant in the local context, namely how the new vaccine compares to
the one that is currently in use, and participants would be exposed
to unacceptable levels of risk from delaying or foregoing a safe
and effective vaccine that is accessible through the public health
system.
Between these two  poles, the use of placebo controls in vac-
cine trials may  be justiﬁed even when an efﬁcacious vaccine exists,
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rovided the risk-beneﬁt proﬁle of the trial is acceptable. This
pplies to situations where the existing vaccine is available through
he local public health system, as well as to situations where the
xisting vaccine is not available locally, or it is only available on the
rivate market. Speciﬁcally, the risk-beneﬁt proﬁle of a placebo-
ontrolled vaccine trial may  be acceptable when (1) the study
uestion cannot be answered with an active-controlled trial design;
nd (2) the risks of delaying or foregoing an existing efﬁcacious vac-
ine are adequately minimized or mitigated; and (3) the use of a
lacebo control is justiﬁed by the potential public health or social
alue of the research; and (4) the research is responsive to local
ealth needs. Importantly, and contrary to many of the existing
thical guidelines on placebo use [4,5,7,9], the acceptable risks of
ithholding or delaying administration of an existing vaccine in the
lacebo arm of vaccine trials may  be greater than minimal when
he above conditions are met.
. Possible situations of acceptable placebo use
The following four scenarios specify situations between the two
oles of clearly acceptable and clearly unacceptable placebo use
n vaccine trials. In these situations, the use of a placebo control
ay  be acceptable when an efﬁcacious vaccine exists, provided the
bove four conditions are met.
.1. Developing a locally affordable vaccine
A new, low-cost vaccine is tested against a placebo because the
xisting vaccine – although known to be, or likely to be, efﬁcacious
n the trial country – is inaccessible in that country’s public health
ystem. Accessibility may  be hindered by limitations in a health
ystem’s ability to provide adequate support in areas including
dministration, ﬁnancing, production, distribution and infrastruc-
ure. Furthermore, there should be strong reasons to believe that
he existing vaccine is likely to remain inaccessible in the future,
nd the new vaccine, if proven efﬁcacious, will not be subject to the
ame limitations that have prevented use of the existing vaccine.
n this situation, a placebo arm might be justiﬁed to assess how
ffective the trial vaccine is compared to no vaccine.
xample. Diarrhoeal disease due to rotavirus infections is a major
ause of morbidity and mortality in India. Two efﬁcacious rotavirus
accines to protect against severe rotavirus gastroenteritis exist
14], but their cost remains prohibitive in many LMICs and experts
ebate the likely local efﬁcacy of the vaccines in some countries.
lthough the existing vaccines were licensed in India, they were
ot – nor were they planned to be – introduced into the national
mmunization programme for reasons of cost and a lack of data
n vaccine efﬁcacy in Indian children. An Indian vaccine company
nd a consortium of partner organizations conducted a placebo-
ontrolled trial of a new low-cost vaccine that was  based on a
train of rotavirus isolated in India and targeted at infants in India
nd other LMICs [15]. To mitigate risk in the placebo arm, the trial
esign included close monitoring of all participants to identify and
reat cases of gastroenteritis as early as possible. This system of
ctive surveillance and early evaluation and treatment signiﬁcantly
educed the mortality risk of severe rotavirus gastroenteritis in the
tudy population.
.2. Evaluating the local safety and efﬁcacy of an existing vaccine
An existing vaccine is tested against a placebo to evaluate its
afety and efﬁcacy in the trial country prior to uptake and intro-
uction into the health system. As there is sometimes insufﬁcient
nformation about the safety and efﬁcacy of existing vaccines in
ifferent settings, the status of an existing vaccine as “established
ffective” in a particular local context may  need to be determined.2014) 4708–4712
Example. A conjugate vaccine against pneumococcal disease,
based on seven serotypes, had been developed and was included
in the routine vaccination programme of many high-income
countries. Although the vaccine was  expected to protect against
pneumococcal disease in Africa, it was unclear if the seven included
serotypes were appropriate for use on this continent. In addi-
tion, there was uncertainty about the burden of disease in Africa,
particularly pneumococcal pneumonia, where a causative agent
cannot be isolated in most cases of pneumonia. Two  additional
serotypes were added to the existing seven-valent vaccine and the
new vaccine was  tested in a placebo-controlled trial in The Gambia,
evaluating the impact of the vaccine against radiologically-proven
pneumonia [16]. The trial showed 37% protection against radiolog-
ical pneumonia, a ﬁnding that has been important in promoting the
use of pneumococcal vaccines in many LMICs.
5.3. Testing a new vaccine when an existing vaccine is considered
inappropriate for local use
A new vaccine is tested against a placebo because scientiﬁc
experts or health ofﬁcials in the trial country have determined that
the existing vaccine should not be used in the national vaccination
programme because it is not considered to be sufﬁciently efﬁca-
cious due to local epidemiologic, demographic, environmental, or
logistical factors. For example, the existing vaccine may provide
inadequate levels of protection, the protection may  not be durable,
or it may  require multiple vaccinations whose timely administra-
tion cannot be ensured under local circumstances. In this situation,
a placebo arm is scientiﬁcally necessary in order to obtain sufﬁ-
cient information on the new vaccine’s efﬁcacy or effectiveness.
An existing vaccine may  also be considered inappropriate for local
use when it is unacceptable to a population, including the potential
study participants in the trial country, based on deeply held cultural
or religious values (e.g. some religions do not approve of the use of
bovine or porcine derived products except in emergency situations
[17], and several vaccines contain such products).
Example. Three new candidate vaccines against leprosy were
tested in a trial in India. Previous evidence indicated that the
existing BCG vaccination offered about 20–30% protection against
leprosy locally. However, Indian health ofﬁcials did not consider
this level of protection sufﬁciently high to justify deploying the vac-
cine through the national immunization programme. The ﬁve-arm
leprosy vaccine trial therefore included two control arms, with one
arm receiving the BCG vaccine and one receiving a placebo. The trial
conﬁrmed the low efﬁcacy of the BCG vaccine and demonstrated
a ∼65% protection for two  of the three new vaccines [18]. For rea-
sons that are unclear, neither of the two  efﬁcacious vaccines was
subsequently included in Indian public health programmes.
5.4. Determining the local burden of disease
An existing vaccine is tested against a placebo because the public
health signiﬁcance of the vaccine’s introduction in the trial country
– that is, the vaccine’s effect on the burden of morbidity and mor-
tality due to the condition(s) against which the vaccine protects –
is unknown or uncertain. Comparison with a placebo yields infor-
mation on the expected public health impact of introducing the
existing vaccine, thereby facilitating informed decisions by public
health ofﬁcials.
Example. Most studies had found low rates of Haemophilus
inﬂuenzae type b (Hib) disease in Asia, and few Asian countries
therefore included Hib vaccine into their routine immunization
programmes. Yet it was unclear whether Hib disease truly is rare, or
whether many cases simply remain undetected. A so-called “vac-
cine probe study” was  conducted in Indonesia to estimate the
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ocal burden of preventable Hib pneumonia and meningitis by
andomizing children in ∼800 hamlets to receive either normal
accinations or normal vaccinations and the existing Hib vaccine
19]. Hib vaccine did not prevent the great majority of pneumonia
ases and the results did not support a major role for Hib vaccine
n overall pneumonia-prevention programmes. However, the study
dentiﬁed high incidences of Hib meningitis and pneumonia which
as used to support the inclusion of Hib vaccine in routine infant
mmunization programmes in many Asian countries.
. Weighing alternative trial designs
When evaluating the acceptability of using a placebo control
n vaccine trials, it is essential for investigators, sponsors, research
thics committees (RECs), and relevant other parties to consider
lternative trial or study designs that might minimize risks and
nhance potential clinical beneﬁts for participants. For example,
n situations where a vaccine is known to be efﬁcacious but the
ocal burden of disease is uncertain, investigators and others should
rst evaluate study designs other than a placebo-controlled trial
hat might allow determining the burden of disease (e.g. measuring
he burden of gastroenteritis before and after introducing rotavirus
accines in Latin America Desai, Oliveira [20]). Furthermore, when
 placebo-controlled trial is thought to be necessary, it is important
o consider a design that combines the investigational vaccine or
lacebo with a routine vaccination and thus avoids giving partic-
pants an additional injection (e.g. pneumococcus vaccine trial in
he Gambia where the experimental vaccine or placebo was mixed
ith the DTP–Hib vaccine [16]).
Investigators and others should also consider enhancing the
otential scientiﬁc and social value of vaccine trials by including
dditional study arms. For example, when the beneﬁts of an existing
accine are uncertain in the local population, testing a new vaccine
gainst both a placebo and the existing vaccine would adequately
nswer the study question, while also providing evidence to eval-
ate the existing vaccine under local circumstances (e.g. leprosy
accine trial in India [18]). However, trials that include an existing
accine as a comparator typically require larger sample sizes and
ence are more resource intensive than trials using a placebo con-
rol alone. The expense, time and trial infrastructure requirements
ntailed by active comparator trials may  discourage investigators
r sponsors from conducting them, thereby delaying the delivery
f new vaccines in populations that may  need them most urgently.
Finally, as part of the discussions around trial design, investiga-
ors, sponsors and RECs should consider different types of “placebo”
nterventions. Rather than using a true placebo control (i.e. an inert
ubstance), it may  be appropriate to use a vaccine against a disease
hat is not the focus of the trial (e.g. an ongoing malaria vaccine
rial provides non-malaria vaccines to participants in the control
rm [21,22]). The motivation for using these types of “placebos”
s to beneﬁt participants in the control arm and avoid giving an
njection with an inert substance. However, this motivation unde-
cores the importance of ensuring that the comparator vaccine(s)
re proven to be beneﬁcial in the study population. Furthermore,
t is important to recognize that trials using such “placebos” may
rovide a less perfect control if the effects of the comparator vac-
ine(s) confound the evaluation of the risk-beneﬁt proﬁle of the
xperimental vaccine. For this reason, use of such “placebos” may
lso be less acceptable to regulators or public health authorities and
otentially delay approval or adoption of a new vaccine.
. Procedural requirementsApplying the above ethical framework requires that investiga-
ors, sponsors, local communities, RECs, drug/vaccine regulators,
ublic health authorities, policy-makers, and other relevant parties2014) 4708–4712 4711
make complex normative and empirical judgments. All of these
stakeholders therefore have an obligation to ensure that decisions
about vaccine trial design, and especially the use of placebo con-
trols when an efﬁcacious vaccine exists, are made based on the best
available evidence and under consideration of all relevant reasons.
7.1. Research ethics review
All vaccine trials should undergo REC review prior to enrolling
participants. Investigators and sponsors are responsible for submit-
ting a research protocol that gives a clear ethical justiﬁcation for
the proposed trial design in line with the above considerations and
presents relevant empirical evidence in a balanced and comprehen-
sible way. The protocol should explain clearly both the scientiﬁc
justiﬁcation for and the social value of using a placebo-controlled
design and discuss the relative merits of alternative trial designs.
The justiﬁcation for not using an existing vaccine as a compara-
tor should include discussion of the acceptability, availability, and
accessibility of the existing vaccine for the prospective trial popu-
lation. It must be clear that the study question cannot be answered
in an active-controlled trial in the target population.
Furthermore, the protocol should provide evidence to support
all empirical claims. This includes relevant evidence from previ-
ous clinical and non-clinical studies; evidence from consultation
with experts (e.g. to support claims about the local safety and efﬁ-
cacy of an existing vaccine); evidence from consultation with local
stakeholders (e.g. to show that the study infrastructure is appro-
priate); and evidence from formative surveys or interviews (e.g.
to demonstrate local acceptability of the vaccine if found effec-
tive). Furthermore, when an existing vaccine is not used in the trial
country because of ﬁnancial, logistical, social, religious or cultural
barriers to access, the protocol should provide evidence that these
barriers are unlikely to be overcome in the foreseeable future, and
that the same barriers would not obstruct use of the experimental
vaccine should it prove efﬁcacious.
RECs are responsible for evaluating research protocols and care-
fully scrutinizing ethical arguments, as well as the evidence to
support empirical claims. RECs should therefore either have mem-
bers who are knowledgeable about vaccine research and vaccine
policy, or they should be open to consulting with independent
experts in this area. Where necessary, sponsors should support
expansion of RECs’ capacity. For instance, independent experts may
present available data to RECs to guide them when evaluating the
adequacy of any local evidence. Importantly, experts can be avail-
able for advice and discussion without participating in the REC’s
actual decision-making process. In some cases, an internationally
coordinated “pre-review” of the study protocol could support local
RECs by mapping the relevant ethical issues posed by the study.
This could be particularly helpful when trials are conducted in
countries where the local ethics review system remains remains
underdeveloped. Finally, to help protect and promote trust and con-
ﬁdence in research oversight, RECs should record their justiﬁcation
for approving a placebo-controlled trial when an efﬁcacious vac-
cine exists, and ideally make it publicly accessible. Study sponsors
could also make this justiﬁcation publicly available in clinical trial
registries.
7.2. Consultation and collaboration with local stakeholders
Early and ongoing consultation and collaboration between
sponsors and host country stakeholders in government and civil
society are essential. Before planning a trial, sponsors should con-
sult with relevant local stakeholders both about the barriers to use
of any existing vaccine(s) and the necessary and sufﬁcient condi-
tions for uptake of a new vaccine. Sponsors should pay particular
attention to political, social and practical issues that may  affect
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ptake. This may  include formative surveys or interviews (e.g. to
ssess the political and economic aspects of the local health sys-
em). Sponsors and investigators are responsible for communicat-
ng appropriately about trial risks with all stakeholders. Risk assess-
ents should be based on the available evidence and local context,
nd they should include the risks of delaying or not conducting the
rial. During the planning and review of vaccine trials, sponsors and
nvestigators should be accessible to local stakeholders to discuss
he often complicated scientiﬁc and epidemiological questions that
re relevant to ethical decision-making. There is no single model
or how such consultation should take place, it may  be ad hoc and
rial-speciﬁc. Where necessary, appropriate structures for ethical
iscussions should be created. Finally, health authorities should
acilitate ethical discussions among all involved parties prior to
pproving a vaccine trial under their jurisdiction, and should make
he outcome of these discussions available to everyone interested.
. Conclusion
Vaccine trial design can raise challenging ethical questions,
specially regarding the use of placebo controls when an efﬁca-
ious vaccine exists. This paper presents an ethical framework
or addressing questions concerning placebo-controlled trials, as
eveloped by a recent WHO  expert panel. The framework sets out
he conditions under which placebo use is clearly acceptable and
learly unacceptable in vaccine trials. It then speciﬁes four situa-
ions in which the use of placebo controls may  be ethically justiﬁed
ven when an efﬁcacious vaccine exists. In these situations, it is
ecessary that the study question cannot be answered in an active-
ontrolled trial design; that the risks of delaying or foregoing the
fﬁcacious vaccine are adequately mitigated; that the risks of using
 placebo control are justiﬁed by the social or public health value
f the research; and that the research is responsive to local health
eeds. The ultimate judgement about the acceptability of using a
lacebo control when an efﬁcacious vaccine exists will depend on
he speciﬁcs of the given trial. It is therefore critical that investi-
ators and sponsors develop the design of vaccine trials in close
ollaboration with host country stakeholders, and that RECs and
thers thoroughly evaluate study protocols based on the available
vidence and all relevant reasons. It is our hope that these recom-
endations will help to ensure that participants in vaccine trials are
rotected from unjustiﬁable risks, while facilitating the conduct of
aluable and urgently needed vaccine research.
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